Penmenvy is a combination of GSK's already-approved vaccines Bexsero and Menveo, which together brought in more than £1.4 billion (around $1.8 billion) in sales last year with double-digit growth ...

The new vaccine is a combination of GSK’s already-approved vaccines Bexsero and Menveo and is designed to protect against meningitis and blood poisoning caused by the A, B, C, W, and Y ...

These are called MenB vaccines and are sold under the brand names Bexsero and Trumenba. The Food and Drug Administration (FDA) approved Trumenba in 2014 and Bexsero in 2015. Both vaccines are approved ...

Newer vaccines include Penmenvy, a 5-in-1 meningitis vaccine made from two FDA-approved vaccines, Bexsero and Menveo. It protects against diseases caused by Neisseria meningitidis serogroups A, B, C, ...

The Centers for Disease Control and Prevention is initiating expanded research into understanding autism and its potential links with vaccines, a source familiar with the CDC’s planning said.

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy.

Mar. 5, 2025 — A live-attenuated tuberculosis (TB) vaccine candidate in development elicits a much more balanced and effective immune response compared to the existing vaccine used across much ...